Press Releases
We’re Delivering the Promise of Healthier Lives.
CURE PHARMACEUTICALÂ
Press Releases
We specialize in optimal formulations to achieve targeted release and exposure of medications.​
CURE Pharmaceutical to Present at LD Micro on December 15, Schedules Investor Video Webcast for December 17
OXNARD, Calif. - CURE Pharmaceutical Holdings ("CURE" or the "Company") (OTCQB: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, today announced that management will present on the company at the LD...
Nicole Kidman Partners With SeraLabs, a CURE Pharmaceutical Company, as a Strategic Business Partner and Global Brand Ambassador
CURE Pharmaceutical Issues Letter to Shareholders
OXNARD, Calif. - CURE Pharmaceutical Holdings ("CURE" or the "Company") (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today that it has issued a letter to its shareholders...
CURE Pharmaceutical Closes $10 Million Financing
- Funds will support the branding & product launch of Cure's consumer products by newly acquired Sera Labs and the advancement of CURE's clinical pharmaceutical pipeline - OXNARD, Calif. - CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of...
CURE Pharmaceutical's® Wholly Owned Subsidiary SeraLabs® Introduces Nutri-Strips™, a Revolutionary Oral Thin Film Strip Technology
SeraLabs Challenges the Status Quo of the Health & Wellness Sector with Nutri-Strips for commercialization and monetization with the launch of first product, Sleep A.S.A.P.CURE Pharmaceutical Holding (OTCQB: CURR) wholly owned subsidiary Sera Labs is challenging...
CURE Pharmaceutical Completes $20 Million Acquisition of Sera Labs, a Leading Health, Wellness and Beauty Brand Marketing and Multi-Channel Distribution Platform Company
- Acquisition to Support Cash Flow Positive Goal in ~18 Months - OXNARD, Calif. - CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October. As previously...
CURE Pharmaceutical to Present at Two Virtual Events in September
CURE Pharmaceutical to Acquire Sera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, in a $20 Million Transaction
CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel
CURE Pharmaceutical Receives NSF’s cGMP Certification for Dietary Supplements
CURE Pharmaceutical Appoints Chief Business Officer
CURE Pharmaceutical Announces Exercise of Warrants for Cash Proceeds of Approximately $1.4 Million and Completes Earn Out Related to 2019 Acquisition
CURE Pharmaceutical Expands to Mexico in Collaboration with Factoria Bogar Subsidiary
CURE Pharmaceutical Expands Cannabis Extraction Patents, Adding Support for CBG for Therapeutic Solutions
CURE Pharmaceutical Secures Chinese Patent on its Oral Thin Films to Treat Erectile Dysfunction
ED Drug Market Expected to Reach US$6.5B by 2025 OXNARD, Calif., March 17, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of Chinese Patent No. ZL201480039313.6. The new patent covers the loading of high amounts of active drug on an oral thin film using its […]
CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific
Vanguard Scientific builds customer trust with CUREinside™ patented methods LOS ANGELES – February 12, 2020 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including both […]
CURE Pharmaceutical Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery
CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines Oxnard, Calif. February 5, 2020 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today that it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups […]
CURE Pharmaceutical to Present at the 12th Annual LD Micro Main Event Investor Conference
CURE CEO to discuss company’s expanded technology platform and pharmaceutical pipeline LOS ANGELES, Dec. 05, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 12th Annual LD Micro Main Event on Wednesday, December 11 at 9:45 AM PST/ 12:45 PM ET at the […]
CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors
Industry veteran brings 40 years of experience to support CURE’s rapid growth OXNARD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience to […]
CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension
OXNARD, Calif., November 14, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents an initial step toward […]
CURE Pharmaceutical Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions
Alternative dosage demand drives company’s manufacturing expansion OXNARD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today. The new line adds […]
CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer
Biopharma star brings extensive translational research experience as company advances its clinical indications Oxnard, Calif. – October 1, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its Chief Scientific Officer. In this role, Dr. Gigi will oversee all CURE’s research and development. Dr. Gigi […]
CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms
OXNARD, Calif. – August 21, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF) drug delivery system, […]
CURE Pharmaceutical Expands Board with Two Women Directors
Oxnard, Calif. – August 7, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings expertise in both […]
CURE Pharmaceutical Secures Patent on High Loading of Active Ingredient in Oral Thin Films
OXNARD, Calif. – July 24, 2019 – CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using its proprietary drug delivery […]